The following is an edited excerpt.
Researchers from the Mayo Clinic in Minnesota have identified variants in two genes that result in a higher chance that prophylactic therapy, using the drugs tamoxifen or raloxifene, will actually prevent breast cancer in high risk women. More studies are needed, but if confirmed, women with these variants may be more likely to undergo the 5 year preventive regimen.
Share this article
Read the full story here: Gene Variations May Predict Response to Breast Cancer Prevention Therapies
